Direct access to China’s clinical research infrastructure, engineered to meet European Medicines Agency (EMA) and Health Products Regulatory Authority (HPRA) standards.
An executive analysis of cross-border clinical development, supply chain optimization, and accelerating time-to-market for Ireland-headquartered life sciences firms.
Ireland has established itself as a top-tier global pharmaceutical and medical device manufacturing center, housing major operations in Dublin, Cork, and Galway. However, local clinical trial execution faces rising cost pressures, constrained patient recruitment pools for multi-center Phase II/III studies, and escalating timelines for early-stage botanical and small-molecule screening.
China offers an unparalleled clinical trial infrastructure backed by massive patient populations, centralized clinical research centers, and ultra-high-throughput bioanalytical laboratories. By partnering with experienced Chinese CROs like MedGence (Yineng Pharma), Irish companies reduce Phase I–IV trial costs by 40% to 60% while accelerating patient enrollment dynamics.
Global regulatory harmonization under ICH-GCP guarantees that clinical trial data generated in NMPA-certified clinical centers in China is fully structured for seamless submission dossiers to the Health Products Regulatory Authority (HPRA) in Ireland and the European Medicines Agency (EMA).
Delivering verifiable clinical data, validated analytical monographs, and scalable CDMO manufacturing for global healthcare enterprises.
Ensuring compliance with EU Clinical Trials Regulation (EU CTR No 536/2014) and HPRA guidelines while safeguarding intellectual property.
We operate strictly on an entrusted contract research and manufacturing model. Under signed NDAs governed by international and Irish commercial contract protocols, all proprietary active ingredient structures, extraction parameters, and clinical outcome metrics remain 100% your exclusive intellectual property.
For botanical active ingredients and natural medicine candidate compounds originating from China, our technical team provides complete bioanalytical validation dossiers (HPLC, HPTLC, GC-MS), stability studies (ICH Q1A-Q1F), and toxicological datasets required for IMPD submission to the HPRA.
A structured 5-phase pathway designed to de-risk clinical candidates prior to European market entry.
Utilizing high-throughput bioassays, we isolate target alkaloids, saponins, and flavonoids from diverse plant origins, evaluating potency changes across harvest seasons and geographic regions to lock in cost-effective raw materials.
Developing chromatographic assay methods and fingerprinting standards to verify compound purity, active concentration, and batch-to-batch consistency for complex natural formulations.
Conducting acute toxicity (LD50), chronic toxicity, cellular metabolic assays, and genotoxicity evaluations in compliant facilities to establish human safety thresholds.
Deploying protocol-driven human trials across accredited clinical hospitals in China, managing ethics committee submissions, patient recruitment, eCRF data monitoring, and biostatistical analysis.
Seamlessly transferring clinical-stage formulations into GMP commercial batch manufacturing across dosage formats: softgels, hard capsules, oral liquids, tablets, and granular powders.
Addressing key strategic queries from Irish clinical procurement officers, medical directors, and R&D executives.
Explore our complete suite of clinical trial services, active ingredient screening, analytical method development, and custom OEM manufacturing.
Connect directly with our scientific directors to review protocol designs, obtain cost estimates, or request analytical assay monographs tailored for European market submission.
Send Inquiry Now